source
- Scribe Therapeutics raises $129 million in gene-editing IPO, debuting on NasdaqScribe Therapeutics completed an initial public offering that raised close to $129 million. The company sold 8.58 million shares at $15 each and will trade on Nasdaq under the ticker SCTX. The off…
- Eli Lilly to file FDA application for obesity drug retatrutide after Phase 3 trial resultsEli Lilly announced that two additional Phase 3 trials of its experimental obesity medicine retatrutide met their primary goals, and the company plans to submit an FDA application for the drug next…